Gimsilumab

Gimsilumab (MORAb-022) is a human anti-GM-CSF monoclonal antibody. Gimsilumab has the potential for the research of COVID-19 and rheumatoid arthritis (RA) [1][2].

Product Specifications

CAS Number

[1648796-29-5]

Product Name Alternative

MORAb-022

UNSPSC

12352203

Target

C-Fms; SARS-CoV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection; Protein Tyrosine Kinase/RTK

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/gimsilumab.html

Purity

98.00

Solubility

10 mM in DMSO

Smiles

[Gimsilumab]

Molecular Weight

(145.765 kDa)

References & Citations

[1]Criner GJ, et al. Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med. 2022 Jun 1;205 (11) :1290-1299. |[2]Crotti C, et al. Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Des Devel Ther. 2017 Jan 13;11:211-223.